AxoGen (AXGN) Q4 2024 earnings summary

Executive summary

• Full-year 2024 revenue reached $187.3 million, up 17.8% year-over-year, with Q4 revenue of $49.4 million, a 15.1% increase, driven by broad-based growth and improved commercial execution.

• Net income for Q4 2024 was $0.4 million ($0.01/share) versus a net loss of $3.9 million in Q4 2023; full-year net loss narrowed to $10.0 million from $21.7 million.

• Adjusted net income for Q4 was $3.5 million ($0.07/share); full-year adjusted net income was $5.9 million ($0.13/share).

• Submitted the Biologics License Application (BLA) for Avance Nerve Graft in Q3 2024, with FDA PDUFA date set for September 5, 2025, and anticipated 12 years of market exclusivity.

• Launched a new strategic plan targeting a $5 billion total addressable market and aiming for a 15%-20% CAGR over the next four years, focusing on elective/planned procedures, breast neurotization, OMS/head and neck, and new markets like prostatectomy.

Financial highlights

• Q4 2024 gross profit was $37.6 million (gross margin 76.1%), up from $32 million (74.6%) in Q4 2023; full-year gross margin was 75.8%.

• Adjusted Q4 EBITDA was $6.7 million, up from $0.6 million in Q4 2023; full-year adjusted EBITDA was $19.8 million versus a loss of $1.1 million in 2023.

• Cash and investments at year-end were $39.5 million, up from $30.5 million at the end of Q3; long-term debt was $50.0 million.

• Net loss per share for the year improved to $0.23 from $0.51 in 2023.

• Marketing expenses as a percentage of revenue decreased to 40.6% from 46.9% year-over-year.

Outlook and guidance

• 2025 revenue growth expected in the range of 15%-17% year-over-year.

• 2025 gross margin guidance is 73%-75%, including ~$2 million in one-time BLA approval costs, impacting margin by ~1 percentage point.

• Expect to remain net cash flow positive for 2025, self-funding the new strategic plan.

• Q1 2025 expected to be a net cash outflow due to annual bonus and sales meeting, with positive cash flow for the remainder of the year.

• FDA review of Avance Nerve Graft underway, with approval expected in September 2025.